Colonic mucosal and enteric neuronal targets

Colonic mucosal and enteric neuronal targets refers to a broad pharmacological site of action rather than a specific molecular entity like a receptor or enzyme (NCATS Inxight). This designation is primarily associated with the drug bismuth subsalicylate, which is used to treat diarrhea, dyspepsia, and Helicobacter pylori infections (PubChem). The therapeutic effect is achieved through multiple pathways: the salicylate moiety inhibits prostaglandin synthesis to reduce intestinal inflammation and hypermotility, while the bismuth moiety provides direct antimicrobial activity and antisecretory effects on the colonic lining (FDA Label). Because the mechanism involves a combination of chemical interactions and physiological responses across different cell types in the gut, it cannot be attributed to a single protein. Consequently, this target serves as a placeholder in clinical databases to describe agents with complex, localized gastrointestinal actions (StatPearls). It is not considered a canonical molecular target in modern drug discovery due to its lack of specificity and defined structure. The interaction with enteric neurons is thought to involve the modulation of local signaling pathways that control gut motility, although the exact receptors remain poorly defined. Overall, this term encapsulates the multifaceted physiological impact of certain antidiarrheal agents on the intestinal environment.

Other names

Unknown/unspecified colonic mucosal and enteric neuronal targetsGastrointestinal mucosal targetsEnteric neuronal targetsBismuth subsalicylate targets

The mechanism of action involves the local release of bismuth and salicylate in the gastrointestinal tract; salicylate provides anti-inflammatory effects by inhibiting prostaglandin synthesis, while bismuth exerts antimicrobial and antisecretory effects (FDA Label; StatPearls).